



Meet Nancy

AGE

65

LOCATION

GEORGIA

DIAGNOSED WITH MODERATE-TO-SEVERE
PLAQUE PSORIASIS

JULY 2016

STARTED ILUMYA® (TILDRAKIZUMAB) 100 MG/ML

SEPTEMBER 2019

Psoriasis Journey

Nancy first started experiencing moderate-to-severe plaque psoriasis symptoms in 2016 when itchy plaques began appearing on her chest. Her symptoms quickly became widespread, and she experienced plaques on other parts of her body – most severely on her legs.

After her symptoms reached their peak, she visited the emergency room and was diagnosed with moderate-to-severe plaque psoriasis that same year.

Nancy is very social – she loves to dine out and meet new people through her storytelling group. Her moderate-to-severe plaque psoriasis symptoms made her self-conscious, so she often chose to stay home rather than going out. When her symptoms were at their worst, she missed out on events with family, friends, and her storytelling group.

Nancy tried numerous topical treatments to ease her moderate-to-severe plaque psoriasis symptoms, but she would still experience occasional flare ups.

“ My psoriasis was extremely painful, covering the majority of my body. ”

Finding ILUMYA®

Working in a medical office herself, it was important for Nancy to find a treatment for her moderate-to-severe plaque psoriasis that was covered by her insurance.

“ During my first visit to the dermatologist, I felt hopeless and wondered if anything could be done for me. Now, I know there is hope and a treatment that works for me. ”

After researching treatments, Nancy learned about ILUMYA® on the website. She then spoke with her dermatologist who provided additional information about potential side effects and treatment coverage options.

Since Nancy received her first two doses, she is experiencing almost completely clear skin without any flare ups.

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy. The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%). These are not all of the possible side effects of ILUMYA®. Call your doctor for medical advice.

Road to Lasting Skin Clearance

Now that she is free from plaques, Nancy is comfortable showing her skin at the swimming pool.

As a storyteller, performing is a big part of her life. Without visible plaques, Nancy feels comfortable wearing a tank top in front of a crowd.

For Nancy, ILUMYA® is fully covered under Medicare Part B, so she does not have to worry about the out-of-pocket cost of her moderate-to-severe plaque psoriasis treatment.

People living with moderate-to-severe psoriasis should talk to their doctor to determine what treatment option may be right for them. For more information about ILUMYA®, and a downloadable doctor discussion guide, visit [ILUMYA.com/talk-with-your-dermatologist](https://www.sunpharma.com/talk-with-your-dermatologist).

Learn more about the moderate-to-severe plaque psoriasis journeys of patients like Nancy [here](#).

ILUMYA® IS IN IT FOR THE LONG HAUL WITH ME



With ILUMYA®, most people with moderate-to-severe plaque psoriasis can achieve clear or almost clear skin in as little as 12 weeks, and 5 years into treatment, it's still going strong.

Here are some reasons to ask your doctor about ILUMYA®:



LONG-LASTING RESULTS

9 out of 10 people who achieved clear or almost clear skin after 1 year were still seeing results 5 years later



WORKS FROM THE INSIDE

ILUMYA® works with the body to balance an overactive immune system, addressing symptoms at the source



DOSING AROUND YOUR SCHEDULE

4 doses a year after 2 starter doses



AFFORDABLE TREATMENT

Eligible patients may pay just \$5 per dose of ILUMYA®*

* \$16,000 maximum program benefit per calendar year. Not valid for patients without commercial insurance coverage or if prescription is paid for by any state or federally funded healthcare program, including but not limited to Medicare, Medicaid, VA, DOD, or TRICARE.

What is ILUMYA?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ILUMYA?

Do not use ILUMYA if you have had a severe allergic reaction to ILUMYA or any of its ingredients.

Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

- feel faint
- trouble breathing or throat tightness
- swelling of your face, eyelids, lips, mouth, tongue or throat
- chest tightness
- skin rash

ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from your psoriasis
- diarrhea or stomach pain
- shortness of breath
- burning when you urinate or urinating more often than normal
- blood in your phlegm (mucus)

Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section “What is the most important information I should know about ILUMYA?”
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA.
- are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

It is not known if ILUMYA is safe and effective in children under 18 years of age.

What are the possible side effects of ILUMYA?

ILUMYA may cause serious side effects. See “What is the most important information I should know about ILUMYA?”

The most common side effects of ILUMYA include upper respiratory infections, injection site reactions and diarrhea. These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects.

You are encouraged to report any negative side effects of ILUMYA to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You are also encouraged to report side effects or ADEs (adverse drug events) to our Drug Safety Department at 1-800-406-7984 or drug.safetyUSA@sunpharma.com (preferred) with as much information as available.

Please read the full [Prescribing Information](#) and [Medication Guide](#) for ILUMYA and discuss any questions with your doctor.